20 articles
A comprehensive review finds SGLT2 inhibitors reduce AKI risk in humans via hemodynamic, metabolic, and cellular protective pathways.
Diabetes drugs like empagliflozin show surprising anti-aging effects — mimicking caloric restriction and reducing senescent cell burden.
Landmark CKD trials enrolled mostly overweight patients — new evidence questions whether SGLT2 inhibitors work for lean, non-diabetic individuals.
A real-world study of 549 patients finds that combining GLP-1 receptor agonists with SGLT-2 inhibitors meaningfully improves glucose control — and baseline HbA1c predicts who benefits most.
New study reveals how the diabetes drug dapagliflozin dramatically alters fat metabolism and kidney function through previously unknown pathways.
A systematic review of 38 trials finds tirzepatide cuts HbA1c nearly 3x more than lixisenatide with similar GI side effect rates.
A landmark Lancet review reveals GLP-1 receptor agonists protect the heart, kidneys, liver, and brain — reshaping how we think about metabolic medicine.
A 10-year Korean cohort study finds GLP-1 receptor agonists don't raise psychiatric risk compared to DPP-4 inhibitors, but show modest signals vs SGLT2 inhibitors.
Review explores how GLP-1 receptor agonists revolutionize type 2 diabetes care through improved blood sugar control and significant weight reduction.
SGLT2 inhibitor canagliflozin prevents cardiovascular harm from low-sodium diets in diabetic kidney disease patients.
A systematic review of 13 studies finds semaglutide and liraglutide meaningfully cut BMI and improve blood sugar in children and adolescents.
Updated review of anti-obesity medications in MASLD finds GLP-1 agonists reduce steatosis and fibrosis, while newer dual/triple agonists show even greater metabolic promise.
A novel endoluminal device implanted in the gut improved insulin sensitivity and weight control beyond what semaglutide achieved in a pig model.
New England Journal review explores the expanding therapeutic potential of GLP-1 drugs beyond diabetes treatment.
New review reveals GLP-1 receptor agonists may directly suppress chronic inflammation across multiple organ systems, far beyond their metabolic benefits.
Carmot Therapeutics tests CT-868, a novel dual incretin receptor agonist, for HbA1c reduction in overweight and obese adults with poorly controlled T2DM.
A landmark JCI review maps the expanding pharmacological arsenal for MASH, from GLP-1 agonists to triple receptor therapies and precision medicine.
A completed RCT tests whether small-sided football sessions 3x/week improve glucose control and metabolic health in T2DM patients on GLP-1 and SGLT2 drugs.
A new review argues that combining GLP-1 receptor agonists with structured exercise and dietary support preserves muscle and delivers lasting fat loss.
Advanced incretin-based therapies show potential for major weight loss while protecting heart, kidney, liver, and brain health.
